Dr. Schweizer discusses HiFiBiO’s unique single-cell technology platform, shares her industry experience, and offers advice for other biotech leaders.
CAMBRIDGE, Mass. – March 3, 2021 – HiFiBiO Therapeutics CEO Liang Schweizer took an opportunity to speak with PharmaBoardRoom and Genialis Podcast to share HiFiBiO’s unique single-cell technology platform and open innovation approach, her capital markets experience, and advice for biotech leaders.
Links to the interviews below:
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company’s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai, and Hong Kong. To learn more, please visit www.hifibio.com.
HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.